NEW YORK, May 12, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Perrigo Co. (NYSE: PRGO), AstraZeneca Plc (NYSE: AZN), Valeant Pharmaceuticals International Inc. (NYSE: VRX), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR) and Mylan Inc. (NASDAQ: MYL). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2325-100free.
--
Perrigo Co. Analyst Notes
On May 7, 2014, Perrigo Co. (Perrigo) released its Q3 FY 2014 (period ended March 29, 2014) financial results and disappointed the street with a 57.0% YoY drop in net income as a result of weak retail environment, a weak cough, cold and flu season, and higher restructuring costs. Perrigo's net income in Q3 FY 2014 declined to $48.1 million, or $0.36 per diluted share, from $111.9 million, or $1.18 per diluted share, in Q3 FY 2013. On non-GAAP basis, the Company's diluted EPS came in at $1.31. Revenues increased 9.2% YoY to $1.00 billion. Perrigo's stock tanked 8.70% on the same day as both the net income and revenues missed analysts' estimates. On average, analysts polled by Reuters expected the Company to report an adjusted diluted EPS of $1.51 on revenue of $1.07 billion. Perrigo now expects its full-year 2014 adjusted EPS to be between $6.15 and $6.30. The full analyst notes on Perrigo are available to download free of charge at:
http://www.analystsreview.com/2325-PRGO-12May2014.pdf
--
AstraZeneca Plc Analyst Notes
On May 6, 2014, AstraZeneca Plc (AstraZeneca) announced that the U.S. Food and Drug Administration (FDA) has approved its EPANOVA (omega-3-carboxylic acids) as an adjunct to diet to reduce triglyceride levels in adults with severe hypertriglyceridaemia (triglyceride levels greater than or equal to 500 mg/dL). The Company informed that EPANOVA is the first FDA approved prescription omega-3 in free fatty acid form. Further, the approval of EPANOVA is based on data from a clinical development programme that included positive results from the Phase III EVOLVE (EpanoVa fOr Lowering Very High triglyceridEs) trial, which examined the efficacy of EPANOVA in lowering triglycerides and other key lipid parameters in patients with very high triglycerides. Briggs Morrison, Executive Vice President, Global Medicines Development and Chief Medical Officer, AstraZeneca, said, "This approval is a significant milestone for AstraZeneca, as it strengthens our existing portfolio of cardiovascular medicines." The full analyst notes on AstraZeneca are available to download free of charge at:
http://www.analystsreview.com/2325-AZN-12May2014.pdf
--
Valeant Pharmaceuticals International Inc. Analyst Notes
On May 8, 2014, Valeant Pharmaceuticals International Inc. (Valeant) released its Q1 2014 earnings. The Company's quarterly total revenues improved 76.5% YoY to $1.89 billion. Valeant's developed market revenues improved 82.2% YoY to $1.4 billion driven by continued growth in the Company's promoted dermatology prescription brands, consumer, neurology and other, and oral health businesses, as well as 9% organic growth in our Bausch + Lomb businesses. The Company's Q1 2014 net loss attributable to Valeant narrowed to $22.6 million, or $0.07 per diluted share, from $27.5 million, or $0.09 per diluted share, in Q1 2013. On a cash EPS basis, adjusted income was $600 million, or $1.76 per diluted share. Analysts at Thomson Reuters expected the Company to post Q1 2014 cash EPS of $1.72 and revenue of $1.97 billion. The full analyst notes on Valeant are available to download free of charge at:
http://www.analystsreview.com/2325-VRX-12May2014.pdf
--
Aegerion Pharmaceuticals Inc. Analyst Notes
On May 6, 2014, Aegerion Pharmaceuticals Inc. (Aegerion) reported Q1 2014 net product sales of $27.0 million, compared to $1.2 million in Q1 2013. While the net product sales from the U.S. grew 24% QoQ, the net product sales in Brazil were adversely affected by longer turn-around times between price quotation and order at the federal level, and delays in receipt of orders from the government of São Paulo. The Company's Q1 2014 net loss stood at $15.8 million, or $0.54 diluted loss per share, compared to net loss of $18.1 million, or $0.64 diluted loss per share, in Q1 2013. The Company has reduced its 2014 global net product sales to $180 million - $200 million from the previous guidance of $190 million - $210 million. The following day, the stock of the Company plummeted 21.60% to end the trading session at $34.63. The full analyst notes on Aegerion are available to download free of charge at:
http://www.analystsreview.com/2325-AEGR-12May2014.pdf
--
Mylan Inc. Analyst Notes
On May 1, 2014, Mylan Inc. (Mylan) reported its Q1 2014 earnings. The Company reported Q1 2014 total revenues of $1.72 billion, up 5.2% YoY. During the quarter, the Company's net revenues from generics segment improved 7.2% YoY to $1.5 billion, while revenues from specialty segment declined 10.5% YoY to $202.8 million. The Company's Q1 2014 net earnings attributable to Mylan's shareholders stood at $115.9 million, or $0.29 per diluted share, compared to net income of $106.9 million, or $0.27 per diluted share in Q1 2013. The adjusted diluted EPS during the quarter increased to $0.66 from $0.61 in Q1 2013. On average, 16 analysts polled by Thomson Reuters expected the Company to post Q1 2014 EPS of $0.63 on revenues of $1.78 billion. The Company has reaffirmed its full-year 2014 adjusted diluted EPS guidance range of $3.25 to $3.60. The full analyst notes on Mylan are available to download free of charge at:
http://www.analystsreview.com/2325-MYL-12May2014.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review
